Study guide
16.3 Headache Disorders & Cranial Neuralgias
MRCP UK
Track your progress as you read
Finished sections get a check mark.
1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy
1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique
2 Clinical Sciences: Cellular, Genetic & Molecular Medicine
2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders
3 Clinical Sciences: Anatomy, Physiology & Immunology
3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions
4 Clinical Sciences: Statistics, Epidemiology & Trial Design
4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification
5 Clinical Pharmacology, Therapeutics & Toxicology
5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols
6 Cardiology: Coronary Artery Disease & Heart Failure
6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation
7 Cardiology: Arrhythmias, Valvular & Pericardial Disease
7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases
8 Respiratory Medicine: Airway & Parenchymal Lung Disease
8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis
9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders
9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing
10 Gastroenterology: Luminal Gastrointestinal Disease
10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia
11 Gastroenterology: Liver, Biliary & Pancreatic Disease
11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis
12 Endocrinology & Diabetes: Diabetes & Thyroid
12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules
13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium
13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease
14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease
14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases
15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance
15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis
16 Neurology: Cerebrovascular, Headache & Demyelinating Disease
16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases
17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease
17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders
18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease
18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies
19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy
19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease
20 Infectious Diseases & Tropical Medicine
20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites
21 Haematology: Anaemias & Red Cell Disorders
21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease
22 Haematology: Malignancy, Coagulation & Transfusion Medicine
22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions
23 Psychiatry in General Medicine
23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law
24 Geriatric Medicine
24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers
25 Dermatology
25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy
26 Oncology & Palliative Medicine
26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control
27 Medical Ophthalmology
27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease
16.3 Headache Disorders & Cranial Neuralgias
Key Takeaways Explain This Topic AI
Migraine involves activation of the trigeminovascular system with calcitonin gene-related peptide (CGRP) release; acute attacks are managed with combination therapy (triptan + NSAID/paracetamol + antiemetic), while prophylaxis (>=2 attacks/month) utilizes propranolol or topiramate (strictly contraindicated in pregnancy due to teratogenicity).
Cluster headache is a trigeminal autonomic cephalalgia characterized by excruciating strictly unilateral periorbital pain lasting 15–180 minutes with ipsilateral autonomic features and marked motor restlessness; acute abortive treatment requires 100% high-flow oxygen at 12 L/min via non-rebreather mask and subcutaneous sumatriptan 6 mg, with verapamil (monitoring PR interval on ECG) as first-line prophylaxis.
Medication-overuse headache develops from frequent regular consumption of triptans/opioids (>=10 days/month) or simple analgesics (>=15 days/month) for >3 months, producing daily chronic dull headache; the definitive treatment is abrupt withdrawal of all culprit medications despite temporary rebound worsening.
Giant cell arteritis (GCA) occurs in patients aged >50 presenting with localized temporal headache, scalp tenderness, jaw claudication, and elevated ESR/CRP; high-dose oral prednisolone 40–60 mg daily (or IV methylprednisolone for visual symptoms) must be initiated immediately to prevent irreversible anterior ischaemic optic neuropathy (AION) without delaying for biopsy.
Idiopathic intracranial hypertension (IIH) predominantly affects obese women of childbearing age, presenting with raised intracranial pressure symptoms, bilateral papilloedema, and normal CSF composition with opening pressure >25 cmH2O; management involves weight reduction, acetazolamide, and optic nerve sheath fenestration or shunting to prevent permanent blindness.
Last updated: September 2026
Headache is one of the most common acute medical presentations encountered in clinical practice and MRCP(UK) examinations. Candidates must distinguish primary headache phenotypes from life-threatening secondary headache disorders, master the pharmacology of acute and preventive headache treatments, and understand the emergency investigation and management of giant cell arteritis, idiopathic intracranial hypertension, and cranial neuralgias.
- 1. Primary Headache Disorders: Migraine
- Pathophysiology & Mechanisms
Trigeminovascular System Activation: Primary neurovascular dysfunction initiates activation of unmyelinated perivascular C-fibres of the ophthalmic division of the trigeminal nerve ( V 1 V_1 V 1 ), which innervate meningeal and pial blood vessels. Activated trigeminal nerve endings release potent vasoactive neuropeptides—predominantly Calcitonin Gene-Related Peptide (CGRP) , Substance P, and Neurokinin A—precipitating neurogenic inflammation, mast cell degranulation, plasma protein extravasation, and intense meningeal vasodilation.
Cortical Spreading Depression (CSD): Migraine aura is caused by CSD—a wave of sustained neuronal and glial depolarization propagating slowly across the cerebral cortex (typically occipital to frontal) at 2 – 5 mm/min 2\text{–}5\text{ mm/min} 2 – 5 mm/min , accompanied by a transient phase of cortical hyperaemia followed by prolonged cortical oligemia (hypoperfusion).
Clinical Phenotypes: With vs. Without Aura
Migraine Without Aura (~75% of patients): Recurrent attacks lasting 4 to 72 hours . Headache has at least two of: unilateral location, pulsating quality, moderate or severe intensity, and aggravation by routine physical activity. Accompanied by at least one of: nausea and/or vomiting, or both photophobia and phonophobia.
Migraine With Aura (~25% of patients): Reversible focal neurological symptoms that develop gradually over ≥ 5 minutes \ge 5\text{ minutes} ≥ 5 minutes and last between 5 and 60 minutes , typically followed by headache within 60 minutes. Visual symptoms are most common: scintillating scotomas (flashing lights), fortification spectra (zigzag jagged lines expanding outward), or central scotomas. Sensory aura involves spreading unilateral tingling followed by numbness.
Acute Abortive Pharmacotherapy
First-line Combination Therapy (NICE Guidelines): Administer simultaneously at the earliest onset of headache:
Oral Triptan: 5 -HT 1 B / 1 D 5\text{-HT}_{1\text{B}/1\text{D}} 5 -HT 1 B /1 D receptor agonist (e.g. oral sumatriptan 50–100 mg, zolmitriptan 2.5 mg, or rizatriptan 10 mg). Triptans promote vasoconstriction of distended meningeal vessels and inhibit trigeminal release of CGRP.
NSAID or Paracetamol: Soluble aspirin 900 mg, ibuprofen 400–600 mg, or naproxen 500 mg (or paracetamol 1 g if NSAIDs are contraindicated).
Prokinetic Antiemetic: Oral metoclopramide 10 mg or prochlorperazine 10 mg to treat nausea and overcome gastric stasis, enhancing analgesic absorption.
Triptan Contraindications: Ischaemic heart disease, previous myocardial infarction, coronary vasospasm (Prinzmetal angina), prior stroke or TIA, peripheral vascular disease, or uncontrolled severe hypertension.
Prophylactic Pharmacotherapy
Indications: Indicated when attacks are frequent ( ≥ 2 attacks per month \ge 2\text{ attacks per month} ≥ 2 attacks per month ), severely disabling despite optimal acute therapy, or in patients at risk of medication-overuse headache.
First-Line Prophylactic Agents:
Propranolol: 80–160 mg daily (non-cardioselective beta-blocker; preferred in non-asthmatic, non-depressed hypertensive patients).
Topiramate: 50–100 mg daily (modulates voltage-gated sodium/calcium channels and GABA/AMPA receptors). Promotes weight loss. Critical Teratogenicity Warning: Topiramate is teratogenic, causing major congenital malformations (cleft lip/palate, microcephaly) and neurodevelopmental disorders; it is strictly contraindicated in pregnancy and in women of childbearing potential unless enrolled in a Pregnancy Prevention Programme.
Second-Line Prophylactic Agents: Amitriptyline (10–50 mg at night, tricyclic antidepressant), Candesartan (16 mg daily, angiotensin II receptor blocker).
CGRP Monoclonal Antibodies: Targeted biologic therapies for refractory chronic or episodic migraine failing ≥ 3 \ge 3 ≥ 3 conventional oral preventatives: Monoclonal antibodies targeting CGRP ligand ( fremanezumab, galcanezumab, eptinezumab ) or the CGRP receptor ( erenumab ).
- 2. Tension-Type Headache & Medication-Overuse Headache
- Tension-Type Headache (TTH)
Features: The most common primary headache disorder. Bilateral, non-pulsating, dull ache with a feeling of tightness or pressure around the head (classic "band-like" or "vise-like" distribution ). Mild-to-moderate intensity; NOT aggravated by routine physical activity (walking, climbing stairs). Lack of severe nausea or vomiting; either photophobia or phonophobia may be present, but not both.
Management: Reassurance, lifestyle optimization, simple analgesics (aspirin, paracetamol, ibuprofen). Avoid codeine/opioids. Chronic TTH ( > 15 days/month > 15\text{ days/month} > 15 days/month ) is managed prophylactically with low-dose oral amitriptyline (10–75 mg nocte).
Medication-Overuse Headache (MOH)
Pathogenesis & Diagnostic Thresholds: Paradoxical transformation of an underlying headache disorder into a daily or near-daily persistent dull headache driven by chronic, frequent intake of acute symptomatic medications:
Triptans, opioids, ergots, or combination analgesics: Consumed on ≥ 10 days per month \ge 10\text{ days per month} ≥ 10 days per month for > 3 months > 3\text{ months} > 3 months .
Simple analgesics (paracetamol, aspirin, NSAIDs): Consumed on ≥ 15 days per month \ge 15\text{ days per month} ≥ 15 days per month for > 3 months > 3\text{ months} > 3 months .
Management: Abrupt, complete cessation of all overused acute abortive medications . Patients must be educated that headaches will temporarily worsen (rebound withdrawal headache, nausea, anxiety, sleep disturbance lasting 1–2 weeks) before significant clinical improvement is observed.
3. Trigeminal Autonomic Cephalalgias (TACs)
The Trigeminal Autonomic Cephalalgias are a distinct group of primary headaches characterized by severe, strictly unilateral head pain accompanied by prominent ipsilateral cranial parasympathetic autonomic symptoms.
Headache Syndrome Demographics & Attack Duration Attack Frequency & Pattern Hallmark Autonomic Features Acute Abortive Therapy Prophylactic Regimen
Cluster Headache Male predominance (3:1) ; typically 20–40 years; strong association with smoking 15 to 180 minutes ; occurs 1 every other day up to 8 times daily; circannual and circadian periodicity (clusters lasting 6–12 weeks; nocturnal attacks waking patient at identical hours) - Ipsilateral conjunctival injection; - Lacrimation; - Nasal congestion / rhinorrhoea; - Forehead/facial sweating; - Partial Horner's (miosis, ptosis); - Motor agitation/restlessness (pacing floor, rocking) 1. 100% High-flow oxygen (12–15 L/min via non-rebreather mask for 15–20 min); 2. Subcutaneous sumatriptan 6 mg (or nasal zolmitriptan 5 mg) 1. Verapamil (240–960 mg daily; mandatory baseline & titration ECGs for PR prolongation); 2. Short-term bridging: Oral prednisolone taper or suboccipital nerve block
Paroxysmal Hemicrania Female predominance (2:1) ; adult onset 2 to 30 minutes ; occurs > 5 times daily > 5\text{ times daily} > 5 times daily (frequently 10–30 attacks/day) Same ipsilateral cranial autonomic features as cluster headache; minimal or no motor agitation Standard analgesics, oxygen, and triptans are completely ineffective Indometacin (oral 25 mg tds titrated to 75 mg tds): Produces a complete, absolute diagnostic and therapeutic response ("indometacin-responsive headache")
SUNCT / SUNA Slight male predominance; age > 50 > 50 > 50 years 1 to 600 seconds (typically bursts of stabbing pain lasting 10–60s); occurs up to 100+ times daily Prominent conjunctival injection and intense lacrimation (SUNCT) or cranial autonomic signs (SUNA); triggered by cutaneous stimulation Ineffective response to triptans or oxygen; IV lidocaine for acute status Lamotrigine is the preventive drug of choice; topiramate, gabapentin
4. Secondary Headache: Giant Cell Arteritis & Idiopathic Intracranial Hypertension
Diagnostic Feature Giant Cell Arteritis (Temporal Arteritis) Idiopathic Intracranial Hypertension (Pseudotumor Cerebri)
Typical Patient Demographics Age > 50 years > 50\text{ years} > 50 years (mean age ~75); female predominance (3:1); associated with Polymyalgia Rheumatica (PMR) in 50% Obese females of childbearing age (typically age 15–45, BMI > 30 kg/m 2 > 30\text{ kg/m}^2 > 30 kg/m 2 ); associated with tetracyclines, retinoic acid (isotretinoin), excessive vitamin A, lithium
Clinical Symptoms - New severe localized temporal or occipital headache; - Scalp tenderness (pain on brushing/combing hair or wearing glasses); - Jaw claudication (pain in masseter muscles while chewing; highest positive predictive value for GCA); - Tongue claudication; - Constitutional symptoms (fever, malaise, weight loss) - Progressive daily headache, characteristically worse upon awakening, coughing, straining, or bending forward; - Transient visual obscurations (TVOs) (fleeting dimming or grey-out of vision lasting seconds with posture changes); - Pulsatile tinnitus ("whooshing" rhythmically synchronous with heartbeat); - Horizontal diplopia (unilateral or bilateral CN VI palsy)
Physical Examination & Fundoscopy - Tender, thickened, nodular, pulseless superficial temporal artery; - Fundoscopy: Anterior Ischaemic Optic Neuropathy (AION) : Chalky-white, swollen optic disc with flame haemorrhages, leading to sudden painless monocular blindness (amaurosis fugax) - Bilateral symmetric papilloedema with blurred disc margins, elevated disc surface, flame haemorrhages, and loss of spontaneous retinal venous pulsations; - Abducens (CN VI) nerve palsy (false localizing sign due to prolonged traction along the petrous temporal bone)
Diagnostic Investigations 1. Inflammatory markers: Markedly elevated ESR ( > 50 mm/h > 50\text{ mm/h} > 50 mm/h , often > 100 mm/h > 100\text{ mm/h} > 100 mm/h ) and elevated CRP; thrombocytosis; 2. Temporal artery ultrasound: Non-compressible hypoechoic circumferential wall oedema ( "halo sign" ); 3. Temporal artery biopsy: Gold standard; shows granulomatous panarteritis with multinucleated giant cells, internal elastic lamina fragmentation, and skip lesions (requires ≥ 2 cm \ge 2\text{ cm} ≥ 2 cm biopsy length) 1. Neuroimaging (MRI + MR Venography): Excludes space-occupying lesion and cerebral venous sinus thrombosis. Shows signs of raised ICP: empty sella turcica , slit-like ventricles, flattening of the posterior sclera, distended perioptic subarachnoid space, and bilateral transverse sinus stenosis; 2. Lumbar Puncture: Opening pressure > 25 cmH 2 O > 25\text{ cmH}_2\text{O} > 25 cmH 2 O (in lateral decubitus position) with completely normal CSF cellular, biochemical, and microbiological composition
Definitive Treatment - IMMEDIATE high-dose systemic corticosteroid therapy :; - Oral prednisolone 40–60 mg daily immediately (never delay for biopsy); - IV methylprednisolone (500–1000 mg daily for 3 days) if visual loss or amaurosis fugax is present; - Bone protection (calcium/vitamin D, bisphosphonate) and PPI; - Tocilizumab (IL-6 receptor antagonist) for steroid-sparing - Weight reduction: The most effective long-term disease-modifying intervention; - Acetazolamide (carbonic anhydrase inhibitor, reduces choroid plexus CSF production); - Topiramate (promotes weight loss and mild carbonic anhydrase inhibition); - Surgical decompression (Optic nerve sheath fenestration, ventriculoperitoneal/lumboperitoneal shunt, or transverse sinus stenting) if progressive visual field loss threatens permanent sight
5. Cranial Neuralgias: Trigeminal Neuralgia
Pathophysiology: Neurovascular compression of the trigeminal nerve (CN V) root entry zone in the cerebellopontine angle, most commonly by an aberrant vascular loop of the Superior Cerebellar Artery (SCA) . Pulsatile vascular compression induces focal mechanical demyelination and ephaptic axonal cross-talk (ephaptic transmission). In younger patients ( < 40 < 40 < 40 years) or bilateral cases, consider a demyelinating plaque of Multiple Sclerosis .
Clinical Presentation:
Paroxysms of intense, excruciating, electric shock-like, stabbing, or lancinating unilateral facial pain lasting milliseconds to 2 seconds .
Confined strictly to the distribution of one or more branches of CN V: V 2 V_2 V 2 (maxillary) and V 3 V_3 V 3 (mandibular) are affected in > 95 % > 95\% > 95% of cases; isolated V 1 V_1 V 1 involvement is rare ( < 5 % < 5\% < 5% ).
Triggered by trivial non-noxious mechanical stimulation of cutaneous trigger zones: light touch, washing, shaving, eating, talking, brushing teeth, or a cold wind.
Followed by a brief refractory period during which triggers fail to elicit paroxysms.
Neurological examination is completely normal ; the presence of sensory loss, absent corneal reflex, or motor weakness mandates neuroimaging to exclude a structural mass (e.g. acoustic neuroma, meningioma) or MS plaque.
Pharmacological Management:
First-Line Therapy: Carbamazepine (100–200 mg twice daily, slowly titrated to 600–1200 mg daily). Inhibits voltage-gated sodium channels. Monitoring Requirements: Full blood count (risk of aplastic anaemia and agranulocytosis), electrolytes (risk of hyponatraemia due to SIADH), and liver function tests. In individuals of Southeast Asian descent, screen for the HLA-B*1502 allele prior to prescribing due to extreme risk of Stevens-Johnson syndrome / toxic epidermal necrolysis.
Second-Line Pharmacotherapy: Oxcarbazepine, lamotrigine, or baclofen.
Surgical Interventions (for medically refractory disease):
Microvascular Decompression (Jannetta Procedure): Posterior fossa craniotomy with surgical transposition of the compressing vascular loop away from the CN V root entry zone, interposing a synthetic Teflon sponge. Provides the highest rate of long-term cure with preservation of facial sensation.
Percutaneous Rhizotomy / Stereotactic Radiosurgery (Gamma Knife): Reserved for patients unfit for open craniotomy; carries risk of sensory loss and corneal anaesthesia.